4 Biotech Buyout Targets for Gilead, Sanofi After Medivation Miss
August 23, 2016 at 09:44 AM EDT
Yesterday, we highlighted six stocks that the folks at Citigroup contend could be buyout targets following Pfizer's ( PFE ) $14 billion purchase of Medivation ( MDVN ). Today, Gabelli's Jing He offers four more-- Incyte ( INCY ), BioMarin Pharmaceutical ( BMRN ), Tesaro ( TSRO ), and Seattle Genetics ( SGEN ). She explains why:
